vs
GERMAN AMERICAN BANCORP, INC.（GABC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是GERMAN AMERICAN BANCORP, INC.的1.0倍（$127.1M vs $126.7M），GERMAN AMERICAN BANCORP, INC.同比增速更快（39.7% vs 17.1%），GERMAN AMERICAN BANCORP, INC.自由现金流更多（$154.0M vs $-26.7M），过去两年GERMAN AMERICAN BANCORP, INC.的营收复合增速更高（22.7% vs 20.8%）
German American Bancorp, Inc.（股票代码：GABC）是一家美国的银行控股企业，专注于提供多元金融服务，核心业务涵盖支付卡相关服务，总部位于纽约曼哈顿下城的巴特利公园城，在金融服务领域拥有成熟的业务布局。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
GABC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.0倍
$126.7M
营收增速更快
GABC
高出22.6%
17.1%
自由现金流更多
GABC
多$180.7M
$-26.7M
两年增速更快
GABC
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $126.7M | $127.1M |
| 净利润 | $35.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 34.6% | -54.6% |
| 净利率 | 28.2% | — |
| 营收同比 | 39.7% | 17.1% |
| 净利润同比 | 53.7% | — |
| 每股收益（稀释后） | $0.98 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GABCZLAB
| Q4 25 | $126.7M | $127.1M | ||
| Q3 25 | $126.5M | $115.4M | ||
| Q2 25 | $123.2M | $109.1M | ||
| Q1 25 | $111.1M | $105.7M | ||
| Q4 24 | $90.7M | $108.5M | ||
| Q3 24 | $88.5M | $101.8M | ||
| Q2 24 | $90.5M | $100.1M | ||
| Q1 24 | $84.1M | $87.1M |
净利润GABCZLAB
| Q4 25 | $35.7M | — | ||
| Q3 25 | $35.1M | $-36.0M | ||
| Q2 25 | $31.4M | $-40.7M | ||
| Q1 25 | $10.5M | $-48.4M | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $21.0M | $-41.7M | ||
| Q2 24 | $20.5M | $-80.3M | ||
| Q1 24 | $19.0M | $-53.5M |
毛利率GABCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率GABCZLAB
| Q4 25 | 34.6% | -54.6% | ||
| Q3 25 | 34.6% | -42.3% | ||
| Q2 25 | 31.8% | -50.3% | ||
| Q1 25 | 12.0% | -53.3% | ||
| Q4 24 | 31.6% | -62.6% | ||
| Q3 24 | 29.0% | -66.6% | ||
| Q2 24 | 29.4% | -76.0% | ||
| Q1 24 | 27.6% | -80.7% |
净利率GABCZLAB
| Q4 25 | 28.2% | — | ||
| Q3 25 | 27.7% | -31.2% | ||
| Q2 25 | 25.5% | -37.3% | ||
| Q1 25 | 9.5% | -45.8% | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 23.8% | -40.9% | ||
| Q2 24 | 22.7% | -80.2% | ||
| Q1 24 | 22.6% | -61.4% |
每股收益（稀释后）GABCZLAB
| Q4 25 | $0.98 | $-0.05 | ||
| Q3 25 | $0.94 | $-0.03 | ||
| Q2 25 | $0.84 | $-0.04 | ||
| Q1 25 | $0.30 | $-0.04 | ||
| Q4 24 | $0.79 | $-0.09 | ||
| Q3 24 | $0.71 | $-0.04 | ||
| Q2 24 | $0.69 | $-0.08 | ||
| Q1 24 | $0.64 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $100.0M | — |
| 股东权益账面价值 | $1.2B | $715.5M |
| 总资产 | $8.4B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资GABCZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务GABCZLAB
| Q4 25 | $100.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $114.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GABCZLAB
| Q4 25 | $1.2B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.0B | $810.8M | ||
| Q4 24 | $715.1M | $840.9M | ||
| Q3 24 | $744.6M | $667.7M | ||
| Q2 24 | $687.8M | $704.2M | ||
| Q1 24 | $655.3M | $762.2M |
总资产GABCZLAB
| Q4 25 | $8.4B | $1.2B | ||
| Q3 25 | $8.4B | $1.2B | ||
| Q2 25 | $8.3B | $1.2B | ||
| Q1 25 | $8.4B | $1.2B | ||
| Q4 24 | $6.3B | $1.2B | ||
| Q3 24 | $6.3B | $985.3M | ||
| Q2 24 | $6.2B | $987.4M | ||
| Q1 24 | $6.1B | $988.4M |
负债/权益比GABCZLAB
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $154.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 121.6% | -21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.46× | — |
| 过去12个月自由现金流最近4个季度 | $267.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流GABCZLAB
| Q4 25 | $159.3M | $-26.0M | ||
| Q3 25 | $51.8M | $-32.0M | ||
| Q2 25 | $26.9M | $-31.0M | ||
| Q1 25 | $37.9M | $-61.7M | ||
| Q4 24 | $95.8M | $-55.8M | ||
| Q3 24 | $24.5M | $-26.8M | ||
| Q2 24 | $18.7M | $-42.2M | ||
| Q1 24 | $23.9M | $-90.1M |
自由现金流GABCZLAB
| Q4 25 | $154.0M | $-26.7M | ||
| Q3 25 | $50.1M | $-35.0M | ||
| Q2 25 | $26.2M | $-33.9M | ||
| Q1 25 | $36.7M | $-63.2M | ||
| Q4 24 | $90.7M | $-58.4M | ||
| Q3 24 | $23.0M | $-28.2M | ||
| Q2 24 | $17.0M | $-42.9M | ||
| Q1 24 | $22.6M | $-91.1M |
自由现金流率GABCZLAB
| Q4 25 | 121.6% | -21.0% | ||
| Q3 25 | 39.6% | -30.4% | ||
| Q2 25 | 21.2% | -31.1% | ||
| Q1 25 | 33.0% | -59.9% | ||
| Q4 24 | 100.1% | -53.8% | ||
| Q3 24 | 26.0% | -27.7% | ||
| Q2 24 | 18.8% | -42.9% | ||
| Q1 24 | 26.9% | -104.5% |
资本支出强度GABCZLAB
| Q4 25 | 4.2% | 0.5% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 1.1% | 1.5% | ||
| Q4 24 | 5.6% | 2.4% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.8% | 0.7% | ||
| Q1 24 | 1.5% | 1.1% |
现金转化率GABCZLAB
| Q4 25 | 4.46× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 3.61× | — | ||
| Q4 24 | 4.13× | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 0.91× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GABC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
